Supramolecular PEGylation of biopharmaceuticals
The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2017
|
| Online Access: | http://hdl.handle.net/1721.1/111202 https://orcid.org/0000-0003-0624-3532 https://orcid.org/0000-0002-2301-7126 https://orcid.org/0000-0002-8227-953X https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 |
| _version_ | 1811076801973190656 |
|---|---|
| author | Vinciguerra, Brittany Thapa, Lavanya S. Jhunjhunwala, Siddharth Isaacs, Lyle Webber, Matthew Appel, Eric Cortinas, Abel Bryan Langer, Robert S Anderson, Daniel Griffith |
| author2 | Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
| author_facet | Massachusetts Institute of Technology. Institute for Medical Engineering & Science Vinciguerra, Brittany Thapa, Lavanya S. Jhunjhunwala, Siddharth Isaacs, Lyle Webber, Matthew Appel, Eric Cortinas, Abel Bryan Langer, Robert S Anderson, Daniel Griffith |
| author_sort | Vinciguerra, Brittany |
| collection | MIT |
| description | The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of therapeutic proteins in formulation, or modifying pharmacokinetics in the body. Toward these objectives, covalent modification with poly(ethylene glycol) (PEG) has been a common direction. Here, a platform approach to biopharmaceutical modification is described that relies on noncovalent, supramolecular host–guest interactions to endow proteins with prosthetic functionality. Specifically, a series of cucurbit[7]uril (CB[7])–PEG conjugates are shown to substantially increase the stability of three distinct protein drugs in formulation. Leveraging the known and high-affinity interaction between CB[7] and an N-terminal aromatic residue on one specific protein drug, insulin, further results in altering of its pharmacological properties in vivo by extending activity in a manner dependent on molecular weight of the attached PEG chain. Supramolecular modification of therapeutic proteins affords a noncovalent route to modify its properties, improving protein stability and activity as a formulation excipient. Furthermore, this offers a modular approach to append functionality to biopharmaceuticals by noncovalent modification with other molecules or polymers, for applications in formulation or therapy. |
| first_indexed | 2024-09-23T10:27:48Z |
| format | Article |
| id | mit-1721.1/111202 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T10:27:48Z |
| publishDate | 2017 |
| publisher | National Academy of Sciences (U.S.) |
| record_format | dspace |
| spelling | mit-1721.1/1112022022-09-27T09:39:20Z Supramolecular PEGylation of biopharmaceuticals Vinciguerra, Brittany Thapa, Lavanya S. Jhunjhunwala, Siddharth Isaacs, Lyle Webber, Matthew Appel, Eric Cortinas, Abel Bryan Langer, Robert S Anderson, Daniel Griffith Massachusetts Institute of Technology. Institute for Medical Engineering & Science Harvard University--MIT Division of Health Sciences and Technology Massachusetts Institute of Technology. Department of Chemical Engineering Koch Institute for Integrative Cancer Research at MIT Webber, Matthew Appel, Eric Cortinas, Abel Bryan Langer, Robert S Anderson, Daniel Griffith The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of therapeutic proteins in formulation, or modifying pharmacokinetics in the body. Toward these objectives, covalent modification with poly(ethylene glycol) (PEG) has been a common direction. Here, a platform approach to biopharmaceutical modification is described that relies on noncovalent, supramolecular host–guest interactions to endow proteins with prosthetic functionality. Specifically, a series of cucurbit[7]uril (CB[7])–PEG conjugates are shown to substantially increase the stability of three distinct protein drugs in formulation. Leveraging the known and high-affinity interaction between CB[7] and an N-terminal aromatic residue on one specific protein drug, insulin, further results in altering of its pharmacological properties in vivo by extending activity in a manner dependent on molecular weight of the attached PEG chain. Supramolecular modification of therapeutic proteins affords a noncovalent route to modify its properties, improving protein stability and activity as a formulation excipient. Furthermore, this offers a modular approach to append functionality to biopharmaceuticals by noncovalent modification with other molecules or polymers, for applications in formulation or therapy. Leona M. and Harry B. Helmsley Charitable Trust (Award 2014PG-T1D002) 2017-09-13T20:03:38Z 2017-09-13T20:03:38Z 2016-11 2016-07 Article http://purl.org/eprint/type/JournalArticle 0027-8424 1091-6490 http://hdl.handle.net/1721.1/111202 Webber, Matthew J. et al. “Supramolecular PEGylation of Biopharmaceuticals.” Proceedings of the National Academy of Sciences 113, 50 (December 2016): 14189–14194 © 2016 National Academy of Sciences https://orcid.org/0000-0003-0624-3532 https://orcid.org/0000-0002-2301-7126 https://orcid.org/0000-0002-8227-953X https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 en_US http://dx.doi.org/10.1073/pnas.1616639113 Proceedings of the National Academy of Sciences Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf National Academy of Sciences (U.S.) PNAS |
| spellingShingle | Vinciguerra, Brittany Thapa, Lavanya S. Jhunjhunwala, Siddharth Isaacs, Lyle Webber, Matthew Appel, Eric Cortinas, Abel Bryan Langer, Robert S Anderson, Daniel Griffith Supramolecular PEGylation of biopharmaceuticals |
| title | Supramolecular PEGylation of biopharmaceuticals |
| title_full | Supramolecular PEGylation of biopharmaceuticals |
| title_fullStr | Supramolecular PEGylation of biopharmaceuticals |
| title_full_unstemmed | Supramolecular PEGylation of biopharmaceuticals |
| title_short | Supramolecular PEGylation of biopharmaceuticals |
| title_sort | supramolecular pegylation of biopharmaceuticals |
| url | http://hdl.handle.net/1721.1/111202 https://orcid.org/0000-0003-0624-3532 https://orcid.org/0000-0002-2301-7126 https://orcid.org/0000-0002-8227-953X https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 |
| work_keys_str_mv | AT vinciguerrabrittany supramolecularpegylationofbiopharmaceuticals AT thapalavanyas supramolecularpegylationofbiopharmaceuticals AT jhunjhunwalasiddharth supramolecularpegylationofbiopharmaceuticals AT isaacslyle supramolecularpegylationofbiopharmaceuticals AT webbermatthew supramolecularpegylationofbiopharmaceuticals AT appeleric supramolecularpegylationofbiopharmaceuticals AT cortinasabelbryan supramolecularpegylationofbiopharmaceuticals AT langerroberts supramolecularpegylationofbiopharmaceuticals AT andersondanielgriffith supramolecularpegylationofbiopharmaceuticals |